engleski

Subtyping of triple-negative breast cancer

Recent researches show a high heterogeneity of triple-negative breast cancers (TNBC).Subtyping of TNBC would better select patients for different therapeutic approaches.That would ensure proper treatment in the early stages of cancer, which increases the effectiveness of treatment and better control of the disease.Based on the expression of AR, CK5/14, EGFR, and PDL1, we cannot fully classify TNBC.However, determining the underlying subgroup (basal-like or luminal) and the expression of markers that may have therapeutic significance (EGFR, PD-L1) stratify patients suitable for tailoredtherapeutic options.

triple-negative breast cancer, subtypes, androgen receptor, CK5/14, EGFR, PD-L1

nije evidentirano